Clues for new therapeutics in osteoporosis and periodontal disease: New roles for lipoxygenases?

Expert Opinion on Therapeutic Targets

Volumn 8, Issue 6, 2004, Pages 643-652

  Serhan, Charles N ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Essential fatty acids; Inflammation; Lipid mediators; Resolution

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOPENTENONE; CYTOCHROME P450; FATTY ACID; ICOSANOID; ICOSAPENTAENOIC ACID; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; LEUKOTRIENE; LIPOXIN; LIPOXIN A; LIPOXYGENASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHOLIPID; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTANOID; TUMOR NECROSIS FACTOR ALPHA;

ATHEROSCLEROSIS; BONE DEFECT; BONE DEVELOPMENT; BONE STRENGTH; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOPOROSIS; PERIODONTAL DISEASE; PERIODONTITIS; PHENOTYPE; REVIEW; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ARACHIDONATE 12-LIPOXYGENASE; ARACHIDONATE 15-LIPOXYGENASE; ARTERIOSCLEROSIS; BONE REMODELING; EICOSANOIDS; ENZYME INDUCTION; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LIPOXINS; LIPOXYGENASE INHIBITORS; MICE; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; PERIODONTITIS; RABBITS; RECOMBINANT FUSION PROTEINS;

EID: 11144284616     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.8.6.643     Document Type: Review

References (52)

1. HOFBAUER LC, SCHOPPET M: Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA (2004) 292:490-495.
2. BOYCE BF, XING L, SHAKESPEARE W et al.: Regulation of bone remodeling and emerging breakthrough drugs for osteoporosis and osteolytic bone metastases. Kidney Int. Suppl. (2003) 85 S2-S5.
3. KLEIN RF, ALLARD J, AVNUR Z et al.: Regulation of bone mass in mice by the lipoxygenase gene Alox15. Science (2004) 303 229-232.
4. KRIEG P, MARKS F, FÜRSTENBERGER G: A gene cluster encoding human epidermis-type lipoxygenases at chromosome 17p13.1: cloning, physical mapping, and expression. Genomics (2001) 73:323-330.
5. HAMBERG M, SANZ A, RODRIGUEZ MJ, CALVO AP, CASTRESANA C: Activation of the fatty acid α-dioxygenase pathway during bacterial infection of tobacco leaves. J. Biol. Chem. (2003) 278 51796-51805.
6. BERGSTRÖM S: The prostaglandins: from the laboratory to the clinic. In: Les Prix Nobel: Nobel Prizes, Presentations, Biographies and Lectures. Almqvist & Wiksell, Stockholm (1982):129-148.
7. SAMUELSSON B, DAHLPÉN SE, LINDGREN JÅ, ROUZER CA, SERHAN CN: Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science (1987) 237:1171-1176.
8. DRAZEN JM, ISRAEL E, O'BYRNE PM: Treatment of asthma with drugs modifying the leukotriene pathway. N. Engl. J. Med. (1999) 340:197-206.
9. BONEWALD LF, FLYNN M, QIAO M, DALLAS MR, MUNDY GR, BOYCE BF: Mice lacking 5-lipoxygenase have increased cortical bone thickness. Adv. Exp. Med. Biol. (1997) 433:299-302.
10. ROWLEY AF, KÜHN H, SCHEWE T (Eds): Eicosanoids and Related Compounds in Plants and Animals. Portland Press, London (1998).
11. SERHAN CN: Endogenous chemical mediators in anti-inflammation and pro-resolution. Curr. Med. Chem. - Anti-Inflammatory & Anti-Allergy Agents (2002) 1:177-192.
12. MCMAHON B, MITCHELL S, BRADY HR, GODSON C: Lipoxins: revelations on resolution. Trends Pharmacol. Sci. (2001) 22 391-395.
13. BONNANS C, VACHIER I, CHAVIS C, GODARD P, BOUSQUET J, CHANEZ P: Lipoxins are potential endogenous antiinflammatory mediators in asthma. Am. J. Respir. Crit. Care Med. (2002) 165:1531-1535.
14. LEVY BD, CLISH CB, SCHMIDT B, GRONERT K, SERHAN CN: Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol. (2001) 2:612-619.
15. LAWRENCE T, WILLOUGHBY DA, GILROY DW: Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat. Rev. Immunol. (2002) 2:787-795.
16. NODE K, HUO Y, RUAN X et al.: Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science (1999) 285:1276-1279.
17. GILLMOR SA, VILLASENOR A, FLETTERICK R, SIGAL E, BROWNER MF: The structure of mammalian 15-lipoxygenase reveals similarity to the lipases and the determinants of substrate specificity. Nat. Struct. Biol. (1997) 4:1003-1009.
18. HAEGGSTRÖM JZ, SERHAN CN: Update on arachidonic acid cascade: leukotrienes and lipoxins in disease models. In: Molecular and Cellular Basis of Inflammation. Serhan CN, Ward PA (Eds), Humana Press, Totowa, New Jersey, USA (1999):51-92.
19. HAMBERG M, SAMUELSSON B: On the specificity of the oxygenation of unsaturated fatty acids catalyzed by soybean lipoxidase. J. Biol. Chem. (1967) 242:5329-5335.
20. RÅDMARK O: Arachidonate 5-lipoxygenase. Prostaglandins Other Lipid Mediat. (2002) 68-69:211-234.
21. KUHN H, WALTHER M, KUBAN RJ: Mammalian arachidonate 15-lipoxygenases structure, function, and biological implications. Prostaglandins Other Lipid Mediat. (2002) 68-69:263-290.
22. HONG S, GRONERT K, DEVCHAND P, MOUSSIGNAC R-L, SERHAN CN: Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood and glial cells: autacoids in anti-inflammation. J. Biol. Chem. (2003) 278:14677-14687.
23. BOCAN TMA, ROSEBURY WS, MUELLER SB et al.: A specific 15-lipoxygenase inhibitor limits the progression and monocyte-macrophage enrichment of hypercholesterolemia-induced atherosclerosis in the rabbit. Atherosclerosis (1998) 136:203-216.
24. GRÜLLICH C, DUVOISIN RM, WIEDMANN M, VAN LEYEN K: Inhibition of 15-lipoxygenase leads to delayed organelle degradation in the reticulocyte. FEBS Lett. (2001) 489:51-54.
25. BERGER M, SCHWARZ K, THIELE H et al.: Simultaneous expression of leukocyte-type 12-lipoxygenase and reticulocyte-type 15-lipoxygenase in rabbits. J. Mol. Biol. (1998) 278:935-948.
26. VANE JR, BOTTING RM (Eds): Therapeutic Roles of Selective COX-2 Inhibitory. William Harvey Press, London (2001).
27. GOH J, GODSON C, BRADY HR, MACMATHUNA P: Lipoxins: pro-resolution lipid mediators in intestinal inflammation. Gastroenterology (2003) 124:1043-1054.
28. HILL EM, ELING T, NETTESHEIM P: Changes in expression of 15-lipoxygenase and prostaglandin-H synthase during differentiation of human tracheobronchial epithelial cells. Am. J. Respir. Cell Mol. Biol. (1998) 18:662-669.
29. SANAK M, LEVY BD, CLISH CB et al.: Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur. Respir. J. (2000) 16:44-49.
30. HUANG JT, WELCH JS, RICOTE M et al.: Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase. Nature (1999) 400:378-382.
31. NASSAR GM, MORROW JD, ROBERTS LJ 2ND, LAKKIS FG, BADR KF: Induction of 15-lipoxygenase by interleukin-13 in human blood monocytes. J. Biol. Chem. (1994) 269:27631-27634.
32. LEVY BD, ROMANO M, CHAPMAN HA, REILLY JJ, DRAZEN J, SERHAN CN: Human alveolar macrophages have 15-lipoxygenase and generate 15(S)-hydroxy-5,8,11-cis-13-transeicosatetraenoic acid and lipoxins. J. Clin. Invest. (1993) 92:1572-1579.
33. SPANBROEK R, HILDNER M, KÖHLER A et al.: IL-4 determines eicosanoid formation in dendritic cells by down-regulation of 5-lipoxygenase and up-regulation of 15-lipoxygenase 1 expression. Proc. Natl. Acad. Sci. USA (2001) 98:5152-5157.
34. SHEN J, HERDERICK E, CORNHILL JF et al.: Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development. J. Clin. Invest. (1996) 98 2201-2208.
35. COTRAN RS, KUMAR V, COLLINS T (Eds): Robbins Patholegic Basis of Disease. W.B. Saunders Co., Philadelphia, USA (1999).
36. LIBBY P: Inflammation in atherosclerosis. Nature (2002) 420:868-878.
37. VAN DYKE TE, SERHAN CN: Resolution of inflammation: a new paradigm for the pathogenesis of periodontal diseases. J. Dent. Res. (2003) 82:82-90.
38. BELMONT HM, ABRAMSON SB: Lupus erythematosus: the role of adhesion molecules and local mediators. In: Molecular and Cellular Basis of Inflammation. Serhan CN, Ward PA (Eds), Humana Press, Totowa, New Jersey, USA (1999):309-324.
39. WEISSMANN G, SMOLEN JE, KORCHAK HM: Release of inflammatory mediators from stimulated neutrophils. N. Engl. J. Med. (1980) 303:27-34.
40. LEKSTROM-HIMES JA, GALLIN JI: Immunodeficiency diseases caused by defects in phagocytes. N. Engl. J. Med. (2000) 343 1703-1714.
41. SERHAN CN, JAIN A, MARLEAU S et al.: Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. J. Immunol. (2003) 171:6856-6865.
42. 4 analogues inhibit leukocyte recruitment to Porphyromonas gingivalis: a role for cyclooxygenase-2 and lipoxins in periodontal disease. Biochemistry (2000) 39:4761-4768.
43. GARCIA RI, KRALL EA, VOKONAS PS: Periodontal disease and mortality from all causes in the VA Dental Longitudinal Study. Ann. Periodontol. (1998) 3:339-349.
44. 4. Impact of aspirin therapy. Circulation (1992) 86:56-63.
45. NATHAN C: Points of control in inflammation. Nature (2002) 420:846-852.
46. MUNGER KA, MONTERO A, FUKUNAGA M et al.: Transfection of rat kidney with human 15-lipoxygenase suppresses inflammation and preserves function in experimental glomerulonephritis. Proc. Natl. Acad. Sci. USA (1999) 96:13375-13380.
47. SERHAN CN: Eicosanoids in leukocyte function. Curr. Opin. Hematol. (1994) 1:69-77.
48. SERHAN CN, CLISH CB, BRANNON J, COLGAN SP, CHIANG N, GRONERT K: Novel functional sets of lipid-derived mediators with and inflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J. Exp. Med. (2000) 192:1197-1204.
49. SERHAN CN, HONG S, GRONERT K et al.: Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter pro-inflammation signals. J. Exp. Med. (2002) 196:1025-1037.
50. MUKHERJEE PK, MARCHESELLI VL, SERHAN CN, BAZAN NG: Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc. Natl. Acad. Sci. USA (2004) 101:8491-8496.
51. SERHAN CN, GOTLINGER K, HONG S, ARITA M: Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis. Prostaglandins Other Lipid Mediat. (2004) 73:155-172.
52. KOBAYASHI T, NARUMIYA S: Function of prostanoid receptors: studies on knockout mice. Prostaglandins Other Lipid Mediat. (2002) 68-69:557-573.